Ellyn Sternfield, a Health Law attorney and Special Counsel in the Mintz Washington, DC office, is quoted in this Bloomberg BNA Health Care Daily Report article covering the request placed on the Department of Justice (DOJ) to look into how Mylan classified EpiPens – as generic drugs – for purposes of the Medicaid drug rebate program in 2007, potentially reaping the company great profit at the expense of taxpayers and the state.

Source

Bloomberg BNA Health Care Daily Report